Oral Antibiotics After 2-Stage Revision for Infected Total Hip Arthroplasty and Total Knee Arthroplasty

Sponsored by Rush University Medical Center

Phase Quota
Phase N/A

The primary purpose of this study is to compare the re-infection rates in patients undergoing 2-stage revision arthroplasty who receive additional oral antibiotic therapy to those patients who received in-hospital perioperative antibiotic only. Patients will be monitored for re-infection following hospital discharge, defined as deep infection of the joint space/capsule that requires return to the operating room within 24-months of the re-implantation procedure.

Study Start Date: July 2011

Estimated Completion Date: December 2016

Specialties: Infectious Disease: Antimicrobials Orthopedics: Clinical Pharmacology,Hip,Knee,Surgical Technique


  • Other: Oral Antibiotics

Inclusion criteria

  • Adult patients undergoing 2-stage revision arthroplasty of the knee or hip with the causative organism(s) identified using tissue culture and/or joint fluid analysis that is amenable to oral antibiotic therapy. Patients must be able to tolerate oral antibiotics and agree to participate in the study

Exclusion criteria

  • Patients with a fungal prosthetic joint infection, unable to tolerate or refuse to undergo oral antibiotic therapy, unable to follow-up at the specified intervals, allergic to the therapy of preference, or have an organism that is not amenable to oral antibiotic therapy

Study Locations And Contact Information

  • Rush University Medical Center, Chicago Illinois
    Contact: Darren R Plummer MBA 312-432-2468
  • Central DuPage Hospital, Winfield Illinois
    Contact: Scott M Sporer MDMS
  • Rothman Institute, Philadelphia Pennsylvania
    Contact: Javad Parvizi MD
  • Rothman Institute, Philadelphia Pennsylvania
  • Rush University Medical Center, Chicago Illinois
  • Central DuPage Hospital, Winfield Illinois

Feature this Clinical Trial

Get your trial in front of 1000s of physicians and patients.
Visit to find out how you can feature this clinical trial.